Vanda Pharmaceuticals
VNDA
NZ$7.85
Share price
-0.43%
Change (1 day)
-22.76%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Cash on Hand
Cash on Hand as of March 2025 : NZ$0.57 Billion
According to Vanda Pharmaceuticals's latest financial reports the company has NZ$0.57 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Vanda Pharmaceuticals - Cash on Hand chart (from 2005 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | NZ$0.66 B | 8.2% |
| 2023-12-31 | NZ$0.61 B | -16.51% |
| 2022-12-31 | NZ$0.73 B | 16.05% |
| 2021-12-31 | NZ$0.63 B | 24.33% |
| 2020-12-31 | NZ$0.50 B | 9.97% |
| 2019-12-31 | NZ$0.46 B | 20.79% |
| 2018-12-31 | NZ$0.38 B | 90% |
| 2017-12-31 | NZ$0.20 B | -1.04% |
| 2016-12-31 | NZ$0.20 B | -2.46% |
| 2015-12-31 | NZ$0.20 B | 26.26% |
| 2014-12-31 | NZ$0.16 B | 4.46% |
| 2013-12-31 | NZ$0.15 B | 8.38% |
| 2012-12-31 | NZ$0.14 B | -23.28% |
| 2011-12-31 | NZ$0.19 B | -25.68% |
| 2010-12-31 | NZ$0.25 B | -9.18% |
| 2009-12-31 | NZ$0.28 B | 253.06% |
| 2008-12-31 | NZ$80.05 M | -28% |
| 2007-12-31 | NZ$0.11 B | 145.79% |
| 2006-12-31 | NZ$45.23 M | -0.75% |
| 2005-12-31 | NZ$45.58 M | 100.03% |
| 2004-12-31 | NZ$22.78 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | NZ$12.07 B | 2,010.83% | 🇨🇭 Switzerland |
 Eli Lilly LLY | NZ$5.40 B | 844.74% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$65.07 B | 11,275.80% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$19.76 B | 3,356.06% | 🇺🇸 USA |
 Pfizer PFE | NZ$29.05 B | 4,979.38% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | NZ$3.26 M | -99.43% | 🇺🇸 USA |
 Merck MRK | NZ$15.48 B | 2,606.89% | 🇺🇸 USA |